PILOT-STUDY OF CYCLOPHOSPHAMIDE PLUS CARBOPLATIN IN ADVANCED OVARIAN-CARCINOMA

  • 1 February 1987
    • journal article
    • research article
    • Vol. 71  (2) , 199-200
Abstract
Six patients with histologically proven stage III-IV ovarian carcinoma received carboplatin (CBDCA) (150 mg/m2) plus cyclophosphamide (1000 mg/m2) monthly for 1 year unless disease progressed earlier. Six other patients received CBDCA (225 mg/m2) with the same cyclophosphamide dose monthly. Continued treatment with the higher CBDCA dose was not tolerable because of myelosuppression, but no other dose-limiting toxic effect was observed. Complete tumor regression was proven at secondary laparotomy in six of the 12 patients, and five of these remain disease-free from 26+ to 28+ months after beginning chemotherapy. Four of these five patients received the higher CBDCA dose.